📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. A summary of the EU Investigational Medicinal Product Dossier (IMPD) — the European counterpart to the information supporting a clinical-trial application.
Why it exists. Under the EU Clinical Trial Regulation, the IMPD gives regulators and ethics committees the quality, nonclinical, and clinical data needed to authorize a trial. It is Europe's equivalent of the IND's supporting package.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. EU Clinical Trial Regulation; IMPD guideline
| Field | Value |
|---|---|
| Document ID | IMPD-EU |
| Version | 1.0 |
| Region | EMA / EU (CTR 536/2014) |
| Standard | EU Clinical Trial Regulation; IMPD guideline |
| Confidentiality | Confidential — portfolio use |
Supports EU clinical-trial authorization (CTA) via CTIS under Regulation (EU) 536/2014. administrative identifiers.
No comments yet. Be the first to say something!
[MOCK]| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Regulatory (EU) | Initial IMPD summary |
Submitted via CTIS; aligned EU assessment; safety reporting (SUSARs, DSUR) per CTR 536/2014 and the Safety Management Plan (TMF-SMP). EU-RMP: RMP-EU.